Newsroom

NEW YORK--(BUSINESS WIRE)--Neurogene Inc. (Nasdaq: NGNE), a clinical-stage company founded to bring life-changing genetic medicines to patients and families affected by rare neurological diseases, today announced that the Compensation Committee of the Company’s Board of Directors approved the grant of non-qualified stock options to purchase an aggregate of 96,450 shares of the Company’s common stock to six new employees (the “Inducement Grants”) on July 6, 2026 (the “Grant Date”). The Inducemen...

LAS VEGAS & RENO, Nev.--(BUSINESS WIRE)--Caesars Entertainment, Inc. (NASDAQ: CZR) (“Caesars”, “the Company”) will release its financial results for the second quarter after the market closes on Tuesday, July 28, 2026. Considering the Company’s pending merger agreement with Fertitta Entertainment announced on May 28, 2026, Caesars will not host an earnings call this quarter. Upon completion of the proposed merger agreement, Caesars’ common stock will no longer be listed on NASDAQ, and the Compan...

STUART, Fla.--(BUSINESS WIRE)--Seacoast Banking Corporation of Florida (NASDAQ: SBCF), a bank holding company whose operating entity is Seacoast Bank, today announced it will release second quarter 2026 results on July 28th, after the market closes. Upon release, investors may access a copy of Seacoast’s earnings results at the company’s website www.SeacoastBanking.com on the home page by selecting “Press Releases” under the heading “News/Events.” Seacoast will host a conference call July 29th...

WESTLAKE VILLAGE, Calif.--(BUSINESS WIRE)--Turn Therapeutics, Inc. (NASDAQ: TTRX), a clinical-stage biotechnology company developing targeted, non-systemic therapies for inflammatory skin diseases, today announced it will host a live webcast on Tuesday, July 7, 2026, to present key findings from the comprehensive interim analysis of its ongoing adaptive Phase 2 trial of GX-03 in atopic dermatitis. The Company will issue a press release tomorrow morning detailing these findings together with the...

NEW YORK--(BUSINESS WIRE)--Definium Therapeutics, Inc. (“Definium” or the “Company”), a late-stage clinical biopharmaceutical company developing a new generation of therapeutics intended to address underlying causes of psychiatric and neurological disorders, today announced the issuance of inducement grants to eight newly hired non-executive employees consisting of options to purchase an aggregate of 169,740 common shares of the Company (the "Options") with effective grant dates of July 6, 2026...

AUSTIN, Texas--(BUSINESS WIRE)--Empery Digital Inc. (NASDAQ: EMPD) (the “Company” or “Empery Digital”) announced today that the Company’s Board of Directors (the “Board”) approved an amendment to the Company’s stockholder rights plan (the “rights plan”) to accelerate the expiration date to the close of business on July 6, 2026. The rights plan was scheduled to expire on February 2, 2027. In deciding to terminate the rights plan, the Board determined that maintaining the rights plan is no longer...

MELBOURNE, Fla.--(BUSINESS WIRE)--L3Harris Technologies (NYSE: LHX) will release its second quarter 2026 financial results after the market closes on Wednesday, July 29, 2026.The company will then host an earnings call on Wednesday, July 29, 2026, at 5 p.m. ET. Participants are encouraged to listen via webcast at L3Harris.com. A replay of the call will also be available on L3Harris.com following the event.About L3Harris TechnologiesL3Harris is the Trusted Disruptor in defense tech. With customer...

TOKYO--(BUSINESS WIRE)--LogProstyle Inc. (NYSE American: LGPS) (the “Company” or “LogProstyle”), headquartered in Minato-ku, Tokyo, Japan, announced today that it will release its financial results for the full fiscal year ended March 31, 2026 (“FY2026”) at 8:00 a.m. Eastern Time on July 13, 2026. In connection with the results, the Company will make available a pre-recorded presentation reviewing its FY2026 financial and operational performance. The presentation will be accessible on the Compa...

SAN FRANCISCO--(BUSINESS WIRE)--Perpetuals.com Ltd (Nasdaq: PDC), anunció hoy que UpsideOnly, su plataforma de negociación libre de riesgo y predicción de mercados, ha registrado un fuerte aumento en el número de nuevos usuarios, superando el importante hito de 100 000 operadores apenas unas semanas después de su lanzamiento, el pasado 19 de mayo. UpsideOnly permite a los usuarios predecir la dirección de los mercados globales de acciones, materias primas, divisas y criptomonedas sin realizar o...

印度达尔瓦德--(BUSINESS WIRE)--(美国商业资讯)-- Shilpa Medicare Limited宣布，其全资子公司Shilpa Biologicals Private Limited已与Orion Corporation签署一项合作开发及供应协议，双方将共同开发并供应静脉注射（IV）纳武利尤单抗生物类似药。该产品以全球应用最广泛的肿瘤免疫治疗药物之一为参照药，双方将携手推动其在欧洲市场的开发与供应，进一步提升欧洲患者获得这一重要治疗方案的可及性。 纳武利尤单抗的问世开启了肿瘤免疫治疗新时代，显著改善了黑色素瘤、肺癌等多种癌症患者的治疗前景。随着其原研药在欧洲即将失去市场独占权，双方此次合作旨在推出一款采用符合欧盟药品生产质量管理规范（EU-GMP）标准生产的高品质纳武利尤单抗生物类似药，使更多欧洲患者能够获得这一重要免疫治疗药物，同时减轻医疗体系负担。根据IQVIA/IMS的数据，纳武利尤单抗2025年在欧洲实现销售额约41亿美元，进一步凸显了这一市场的巨大潜力。 根据协议，Orion将拥有该纳武利尤单抗生物类似药在欧洲市场的独家注册、商业化推广、分销及销售权。S...